Sirtex Medical. Sirtex Medical Inc. 6 billion takeover by US cancer care company Varian. , and product for the U. This animated Mode of Action video has been created by Sirtex Medical to serve as an educational resource that provides a narrative look at Selective Internal Radiation Therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres. , Jan. Join LinkedIn today for free. According to  Sirtex is providing treatment options for patients with cancers of the liver. 30, 2018 /PRNewswire/ -- Varian Signs Agreement to Acquire Sirtex. The companies first announced that they inked a deal for Varian to acquire all of Sirtex's outstanding shares in January this year. Salaries, reviews, and more - all posted by employees working at Sirtex Medical. 18 May 2017 Sirtex Medical Inc. As I write Sirtex stock is down 41%, making people think the 30 Jan 2018 Sirtex added in a statement its board unanimously recommends that its shareholders vote in favour of the offer. 29 Jan 2018 Varian (NYSE: VAR) today announced that it will webcast a conference call to discuss the details of the agreement, also announced today, to acquire all the outstanding shares of Sirtex Medical 31 Jul 2017 That's what most shareholders in Sirtex Medical Limited (ASX:SRX), a life-sciences company which develops novel small particle technology treatments to treat liver tumours, have been contemplating for almost a year. Sirtex's vision is that one day cancer will no longer be a  17 Jan 2018 Shares in Sirtex Medical jumped after the liver cancer treatment group announced a better than expected lift in earnings. The company is focused on interventional oncology therapies and is a global leader in radioembolization. SRX shares are down nearly 50% over the past year as it failed to deliver big-growth  An innovative nanomedical product has been manufactured at Industriepark Höchst since the start of 2014: SIR-Spheres, a minimally invasive cancer treatment developed and provided by Sirtex Medical Ltd. 6 billion takeover proposal from Varian Medical Systems of the US, has lifted its first-half net profit by 13 per cent and maintained its earnings guidance for the full year. Change the date range, chart type and compare SIRTEX MED FPO against other companies. Contact Us. The company has had regulatory approval to sell SIR-Spheres in Australia since 1997 and the US and Europe since 2002. 5 . com or find the latest updates on the SIR-Spheres Y-90 resin microspheres Facebook page. Find financial news for Sirtex Medical Limited (ASX:SRX) using Google Finance. Learn about working at Sirtex Medical Limited. Global. W10-U-0214  Sirtex Medical Limited is an Australian-based medical device company, providing a radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres. 31 Jan 2018 Sirtex, which specializes in interventional oncology, suffered numerous setbacks in 2017, including the firing of its CEO and disappointing clinical trial results. The SIR-Spheres procedure infuses millions of radiactive microspheres into the liver where they selectively target  30 Jan 2018 Australian-listed Sirtex Medical is set to be sold to a US company for $1. The device is based on  HotCopper has news, discussion, prices and market data on SIRTEX MEDICAL LIMITED. Contact or follow us. Thanks to slower SIR-Spheres sales, Sirtex's constant currency EBITDA in 1H17 will fall 9-16%. agreed to buy Australia’s Sirtex Medical Ltd. 31 Jan 2018 Shares in biotech firm Sirtex have climbed almost 50 per cent after a proposed $1. 1 Feb 2018 Sirtex Medical Systems is an Australia-based life sciences company with a presence around the globe. S. The first of these is SIR-Spheres®, which are  8 Feb 2018 A cross-border team from global law firm Norton Rose Fulbright is advising US-based medtech giant Varian Medical Systems, Inc. Sirtex Medical Europe GmbH was founded in September 2003 after its Australian parent company received European approval (CE mark) to sell its product, SIR-SpheresTM microspheres. U. 00 per share. It offers targeted radiation therapy known as SIR-Spheres Y-90 resin microspheres. 3B proposed buyout of Sirtex Medical (ASX:SRX), Varian reported today. Using technology initially developed at the Cancer Research Institute Inc (CRI) of Western Australia, Sirtex has three products at various stages of development. View the basic SRX. • Reference Unlabeled/Unapproved uses of drugs or products: Histoacryl, B. Device Generic Name: Radioactive Implant (Yttrium-90 microspheres). company to add radiation medicine to its portfolio for cancer treatments. AX stock chart on Yahoo Finance. Days like today make me wish I was back in stockbroking because Sirtex's 'Trading Update' has created the kind of contrarian play I love. SIR-Spheres® microspheres are about one third SIR-Spheres Delivery Set and Sirtex V-vial. A short time ago, the shares were up 12. on its proposed AU$1. for about A$1. 3 billion). Radioembolization is a minimally invasive therapy for the treatment of liver cancer. 58 billion in a deal that offers shareholders a significant premium as interest in the cancer space continues to drive activity. 6 billion takeover of biotech company Sirtex by US cancer care firm Varian, but a higher takeover bid might. 70, triggered by a takeover offer of $28. Toronto, Canada. The liver cancer treatment company (SRX) announced that after reviewing a list of unsolicited offers late last  Established in 1997, Sirtex Medical Ltd aims to become the world leader in liver cancer treatment products. 30 Jan 2018 PALO ALTO, Calif. 6 billion ($1. Its clinical programs include SIRFLOX, FOXFIRE/FOXFIRE Global, SARAH, SIRveNIB, and SORAMIC. 29 Jan 2018 Varian Medical Systems Inc. cancer-treatment company Varian Medical Systems is buying Australian liver-cancer treatment maker Sirtex Medical for $1. Sirtex chief executive Andrew McLean would not speculate on whether there would be other bids for the company, but confirmed that Varian's all-cash takeover offer of  31 Jan 2018 Sirtex Medical's second-biggest shareholder, Allan Gray, is throwing its weight behind the $1. sirtex. Name. The infringement notice  Maurice Blackburn, in partnership with litigation funder IMF Bentham, has announced a class action against Sirtex Medical Limited. SIRT using SIR-Spheres microspheres is a targeted liver tumor treatment that delivers  29 Jan 2018 U. 3 billion, the latest in a wave of big M&A deals sweeping the global healthcare sector. It is proposed  28 Jun 2017 IMF Bentham is funding a shareholder class action against Sirtex Medical Limited (ASX:SRX) (Sirtex) in respect of allegations concerning its conduct and that of its former Chief Executive Officer, Mr Gilman Wong, during the period from 24 August 2016 to 16 December 2016 (inclusive) (Relevant Period). 1 Feb 2018 A looming class action is unlikely to stop the proposed $1. 20 Sep 2017 17-320MR Sirtex pays penalty for alleged continuous disclosure breach. Sirtex manufactures and distributes the SIR-Spheres microspheres, an innovative treatment for liver cancer. It is one of the few biotechs to commercialise its technology. headquarters are located in Woburn, Mass. Sirtex Medical Ltd. Sirtex was established in 1997. , a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted liver cancer therapies, today announced the. The transaction  Morningstar provides investment research for stocks, funds, ETF's, credit, and LIC's as well as financial data, news, and investing articles and videos. com staff  Australian-based global healthcare business Sirtex Medical Limited, with help from researchers from the University of Sydney, is undertaking ground-breaking research and development that has the potential to improve how diseases such as brain cancer are treated. SIR-Spheres® is a  20 Dec 2016 Shares in Sirtex Medical Limited (ASX:SRX) plunge following a trading update. The developer of an internal radiation therapy for liver cancer made a net profit of $23. Sirtex's U. 6 billion takeover of the biotech with the hefty near 50 per cent premium too good to pass up. Join the HotCopper ASX share market forum today for free, page-1. Disclaimer | Copyright | Privacy Information. ®SIR - Spheres is a registered trademark of Sirtex SIR - Spheres Pty Ltd. See who you know at Sirtex Medical Limited, leverage your professional network, and get hired. %% to $17. The procedure is commonly known in the medical community as Selective Internal Radiation Therapy (SIRT). 20 Feb 2018 Biotech Sirtex Medical, which is subject to a $1. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments. Chief Executive of Sirtex Nigel Lange discusses how the company is transforming the market for oncological therapies. 58bn acquisition of all of the issued share capital of ASX-listed life sciences company Sirtex Medical Limited, currently the largest takeover deal  4 Aug 2017 Sirtex Medical Limited (ASX: SRX) faces a proposed shareholder class action to be run by specialist litigation firm William Roberts Lawyers with the financial backing of the long standing and experienced litigation funder, Litigation Lending Services, which since 1999 has funded around 200 matters. Acquisition to expand Varian's cancer care portfolio. 61. SRX's key product is SIR-Spheres microspheres, the  October 11, 2016—Sirtex Medical Ltd announced the commencement of SIRCCA (Selective Internal Radiation Therapy [SIRT] in Cholangiocarcinoma), a phase 2 study of the company's SIR-Spheres yttrium-90 (Y-90) resin microspheres in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). Sirtex Medical Limited (SRX) is a biotechnology and medical device group whose primary objective is to provide effective liver cancer treatments utilising small particle technology to approved markets in Asia Pacific, Americas, Europe, Middle East and Africa (EMEA). According to  31 Jan 2018 Sirtex Medical Ltd (ASX:SRX) was the big gainer on the ASX this morning as its shares surged 45% to hit a high of $27. market is currently produced at the company's manufacturing facilities in Wilmington, Mass. 3 billion) in a bid by the U. Sirtex is a global life-sciences company that develops and delivers effective oncology treatments using novel small particle technology. The company said EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) for the six months to December is  Sirtex Medical Ltd (SRX:ASX) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. antitrust authorities and the German Federal Cartel Office cleared Varian Medical's (NYSE:VAR) $1. See what employees say it's like to work at Sirtex Medical. ASX-listed company Sirtex Medical Limited (Sirtex) has paid a penalty of $100,000 after ASIC issued an infringement notice for an alleged failure by Sirtex to comply with its continuous disclosure obligations. The company has entered into a binding scheme implementation deed with Varian Medical Systems, Inc (NYSE:VAR). Sirtex investors will receive A$28 in cash for each share, Palo-Alto The latest Tweets from Sirtex Medical (@SirtexMedical). The company is currently headed by Andrew McLean, who was appointed as CEO on June 5, 2017. Ph. For more information visit www


copyright © 2006 Contact us | Site map